Eli Lilly and rival drugmaker Novo Nordisk are the leading companies in the GLP-1 space, but others are emerging. Among them ...

The family of a young girl who was hit and killed by a drug driver have described the decision to reduce his time behind bars ...

The ex-taxi driver who had cocaine in his system had also been using his phone before he killed Lily, who was out buying ...

Eli Lilly beats Q3 2025 estimates and raises guidance as strong GLP-1 drug sales from Mounjaro and Zepbound lift profit and ...

In today’s Pharmaceutical Executive Daily, we cover Pfizer’s lawsuits against Metsera and Novo Nordisk over alleged ...

The decision to discontinue production was driven by business considerations rather than concerns about the product’s safety or effectiveness.

Pedersen, Maggie Fick and Bhanvi Satija COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year forecasts on ...

In today’s ACT Brief, we explore how Eli Lilly’s orforglipron could become the first oral GLP-1 therapy reviewed under FDA’s new national priority program, and examine emerging regulatory and ethical ...

Pfizer raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for slow sales ...

Daniel Hyden was found guilty on four counts of second degree murder after driving into a crowd people celebrating July 4, 2024 in a Lower East Side park.

Shares in Metsera shot up nearly 20% to more than $72 after news of the renewed bidding war emerged, raising its market ...

The AI chip darling already has the most cutting-edge products and the best customers. The next thing to do is to find more of them.